Tessera
6 known investors
Tessera Therapeutics develops Gene Writing, a genome engineering technology platform designed to make permanent alterations to the human genome for treating diseases. The company focuses on non-viral delivery methods to enable potentially curative genetic therapies.
Investors · 6
In the news
- Can AI Break the ERP Change-Order Cycle? Tessera Labs Just Raised $60M to Tryerp.today · 2026
- Tessera Labs Raises $60 Million to Speed Enterprise Overhauls | Contract Pharmacontractpharma.com · 2026
- Tessera Labs Raises $60M in Fundingfinsmes.com · 2026
- Tessera Labs Raises $60M in Funding Led by Andreessen Horowitz to Transform ERP Modernizationbusinesswire.com · 2026
- Sell or Invest in Tessera Therapeutics Stock Pre-IPOnasdaqprivatemarket.com · 2024
- Tessera Therapeutics Raises Over $230M in Series B Financing - FinSMEsfinsmes.com · 2021